SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $614,879,440 |
| Positions | 485 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $4,076,485 | 122,087 |
| KYMERA THERAPEUTICS INC | KYMR | COM | $3,954,395 | 34,485 |
| IDEAYA BIOSCIENCES INC | IDYA | COM | $3,823,231 | 102,582 |
| VAXCYTE INC | PCVX | COM | $3,641,147 | 62,638 |
| AFFIRM HLDGS INC | AFRM | COM CL A | $3,585,590 | 43,968 |
| CELLDEX THERAPEUTICS INC NEW | CLDX | COM NEW | $3,537,517 | 95,069 |
| LOAR HOLDINGS INC | LOAR | COM SHS | $3,519,433 | 43,660 |
| MIRUM PHARMACEUTICALS INC | MIRM | COM | $3,503,203 | 29,924 |
| DOORDASH INC | DASH | CL A | $3,490,385 | 18,915 |
| KRYSTAL BIOTECH INC | KRYS | COM | $3,474,743 | 9,349 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.